AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Suspension for injection - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis A vaccine
Description: Suspension for injection - intramuscular
Study NCT05165225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
Description: Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m\^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m\^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m\^2 d1 iv Q3W for 4 cycles
Study NCT05132868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video and pamphlet
Description: The primary intervention in this study is watching the video or reading the pamphlet in advance of the genetic counseling session, which overview the same information that we currently provide in-person/via telehealth during the genetic counseling session.
Study NCT05132868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional genetic counseling
Description: Patients will receive traditional genetic counseling
Study NCT05132868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional genetic counseling
Description: Patients will receive traditional genetic counseling
Study NCT05307978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1910
Description: Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
Study NCT05307978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
Study NCT05374668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based Yoga Exercises
Description: They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
Study NCT05554939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic CD19-CAR-γδT cell
Description: Phase 1 dose escalation (3+3) : dose 1 (6 × 10\^6 cells/kg) , dose 2 (1.2 × 10\^7 cells/kg), dose 3 (1.8 × 10\^7 cells/kg); Phase 2 : dose of RP2D.
Study NCT05554939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
Study NCT05554939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
Study NCT06302985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: atomized inhalation ICG before thoracoscope pneumonectomy
Description: Preoperative preparation ICG solution dissolved in 5ml of normal saline (dose 0.5mg/kg) was inhaled 30 minutes before surgery.~Operation method After entering the chest cavity, the fluorescence endoscope was switched to the fluorescence display mode, and the fluorescence-stained normal lung tissue and non-stained lesion tissue could be clearly displayed through the display screen, and the external boundary of the lesion was marked with an electric hook. The mediastinal pleura and pulmonary pleura were opened along the boundary of the lesion, and the lung tissue was split along the gap between the lesion and the lung tissue with an electric coagulation hook and an ultrasonic knife, and the lesion arteries and bronchi were freed.
Study NCT06024538 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor samples
Description: Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
Study NCT04906382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Given IV
Study NCT05599269 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Examination of dentures with SR Phonares II teeth
Description: The intraoral situation will be examined similar to a standard dental examination. The dentures are then removed, cleaned and examined extraoral. Pictures and an impression of the dentures are taken.
Study NCT05650060 — intervention group
Intervention type: DRUG
Intervention: Secukinumab
Description: all patients with psoriasis who received secukinumab
Study NCT05203055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b
Description: 180μg/w
Study NCT05452772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Participants will received two psilocybin sessions, 1 week apart
Study NCT05452772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: Participants will received two niacin sessions, 1 week apart
Study NCT05264415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC)
Description: Trauma-informed, family-centered, skill-building preventive intervention for families with preschool-aged children.
Study NCT05264415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Education Website
Description: A website providing parenting education resources in four primary domains relevant for families with preschool-aged children (parenting, child development, transitions, and self-care).
Study NCT06259084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seedchrony
Description: The seedchrony probe is coupled to the transfer catheter. When the transfer catheter is placed inside the uterus, the probe measures the biomarker concentraction in the fluid entering the catheter. The measurements last two minutes.
Study NCT04634838 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MedCu Antibacterial Wound Dressings with Copper Oxide
Description: Comparison between the efficacy of antibacterial wound dressings containing copper oxide microparticles to improve the wound healing of pressure sores and post-op wounds as compared to silver wound dressings
Study NCT05203055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleotide Analog
Description: Etecavir 0.5mg qd or Tenofovir 300mg qd
Study NCT05203055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pulse peginterferon alpha-2b
Description: 180μg/w for 8 consecutive weeks and cessation for 4 weeks
Study NCT06053463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily disposable multifocal soft contact lens
Description: Daily disposable multifocal soft contact lens that will be worn for 1 month.
Study NCT06001684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBR854 Cell Injection
Description: The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
Study NCT06188260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane COMPLETE Lubricant Eye Drops
Description: Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant
Study NCT05854628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Skin biopsies will be obtained at different time points.
Study NCT05854628 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: skin biopsy
Description: Skin biopsies will be obtained at different time points.
Study NCT06280729 — intervention group
Intervention type: OTHER
Intervention: AI-Analyis
Description: The study will investigate classification (ie logistic regression, decision tree, random forest, support vector machine, K nearest neighbour, naive bayes) ML models and treatment effect estimation ML models (T-learner, X-learner..).
Study NCT06090357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar pressure
Description: Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.
Study NCT05989737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Enhanced Behavior Therapy
Description: 8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
Study NCT05793099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of aqueous propolis gums in salivary and dental plaque pH in children
Description: The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given aqueous propolis gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing aqueous propolis gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured.
Study NCT05793099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Effect of placebo gums in salivary and dental plaque pH in children
Description: The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given placebo gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing placebo gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured.
Study NCT04812483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag (Revolade®)
Description: Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
Study NCT04812483 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: standard therapy (without eltrombopag): HD-DXM
Description: standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
Study NCT04812483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy (without eltrombopag): HD-DXM
Description: standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
Study NCT05933603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine and Oxybutynin (ato-oxy)
Description: 0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly
Study NCT06239753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization
Description: Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes. Application of Dynamic Neuromuscular Stabilization (DNS).
Study NCT06239753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Prenatal Education Program Implementation
Description: Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes.
Study NCT04787809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Well
Description: Living Well is a single session digital intervention that aims to decrease experiential avoidance and increase engagement in values-consistent behavior.
Study NCT06439706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling
Description: HPV self-sampling kit
Study NCT06439706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Self-Sampling
Description: HPV self-sampling kit
Study NCT06439706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Education
Description: Small-group education led by bilingual health educator
Study NCT04973696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toolkit for Optimal Recovery after Orthopedic Injury
Description: The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
Study NCT04973696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Enhanced Usual Care (MEUC)
Description: The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
Study NCT05232981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligation of the bilateral internal iliac arteries
Description: opening the posterior peritoneum overlying the bifurcation of the common iliac arteries. Then careful dissection of the internal iliac artery is carried out on each side and the anterior division of the internal iliac artery is ligated 4 cm below the bifurcation of the common iliac on both sides by single ligation procedure using Vicryl 1.0 .~Re-checking of the femoral pulsation of both sides is performed. Then, the placenta is removed manually in a piecemeal manner, any remaining bleeding points from the placental site are then controlled by hemostatic sutures .
Study NCT05232981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shehat's technique
Description: The three-step technique (Shehata's technique) entailed 3 steps, the first step is double bilateral ligation of uterine arteries before placental separation. Uterine artery ligation is made at 2 levels. First will be done at the isthmus and second will be done 1 cm above the cesarean incision. Regarding timing of ligation , we will apply the uterine artery ligation before placental separation to minimize blood loss at the attempt of placental separation.~Placenta is separated manually either totally or in piecemeal. If manual separation failed, placenta is removed by scissors.~Application of quadruple sutures is done at the lower uterine segment to compress and secure the neovascularization in the bed of placenta.~Insertion of triple way catheter is commenced from inside the uterine incision downwards using long artery forceps or uterine sound and the pulled by the assistant from below. The catheter balloon is inflated by 50 cc saline and left for 48 hours
Study NCT04792515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with SOX/ or apatinib
Description: Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing.
Study NCT05379868 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior column osteotomy
Description: Apical full facet joint resection. Study intervention does not involve a device.
Study NCT05379868 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No osteotomies
Description: Standard treatment
Study NCT06630312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha galactosidase
Description: Alpha galactosidase capsule, 600 GALU, manufacturer Equate brand, Walmart. Powder contents from one capsule were stirred into 16 g spaghetti sauce and served before the main meal.
Study NCT06630312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is 16 gm of spaghetti sauce served before the meal in a condiment cup. It is the same set up as the intervention except the \&#39;intervention\&#39; contains the AGS.
Study NCT06268301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide oral suspension
Study NCT02028975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measure the threshold of detection for linoleic acid
Study NCT02028975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral stimulation tests
Study NCT02028975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Venous blood samples
Study NCT02028975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Samples for genetic studies (ancillary study)
Study NCT04944095 — intervention group
Intervention type: OTHER
Intervention: Change in SARS-CoV-2 Antibody Levels
Description: Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
Study NCT05216003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH4YOU
Description: PATH4YOU offers patient-center, comprehensive, contraceptive counseling; pregnancy planning; and same to next day access to birth control. This clinical care program will reduce obstacles to contraception in Indiana and enables access to healthy pregnancy planning conversations.
Study NCT01069614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TopClosure 3S System
Study NCT05579288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O/O2)
Description: Nitrous oxide (N2O/O2) for pain alleviation
Study NCT05579288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (O2)
Description: Oxygen (O2) as placebo for control group
Study NCT03733535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
Study NCT06398834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: In the esketamine combined with butorphanol group (Group BK), patients received an intraoperative intravenous infusion of esketamine (0.3 mg/kg/h) followed by postoperative patient-controlled intravenous analgesia (PCIA) (esketamine 1.5 mg/kg + butorphanol 0.15 mg/kg + azasetron 20 mg).
Study NCT06398834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butorphanol
Description: In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.
Study NCT06398834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.
Study NCT03733535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129 Xenon
Description: 1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
Study NCT06460662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques
Study NCT06460662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques
Study NCT06297902 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose painting
Description: Dose painting
Study NCT05629572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity
Description: Paired whole blood and plasma samples collected at multiple time points.
Study NCT06569940 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sleepiz One+
Description: In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 42 minutes.